Deficiencies in the mismatch repair (MMR) machinery lead to DNA defects that cause cancer. Cancers that exhibit MMR deficiency are typically resistant to cisplatin and carboplatin, but can be treated in part with oxaliplatin. Recently, we have shown that rhodium metalloinsertors, which bind DNA at mismatched sites with over 1000 fold selectivity, exhibit antiproliferative and cytotoxic activity selectively in cells that are MMR-deficient. A bimetallic complex, consisting of a rhodium metalloinsertor tethered to an oxaliplatin derivative, was synthesized to improve platinum efficacy in an MMR-deficient human colorectal carcinoma line (HCT116O). The addition of the rhodium metalloinsertor significantly increases cytotoxic activity and whole-cell platinum uptake compared to that of unconjugated platinum, as well as cisplatin and oxaliplatin. DNA binding studies show that the complex interacts with DNA through both metalloinsertion at a mismatch as well as the formation of Pt-DNA crosslinks.

Synthesis and characterization of a heterobimetallic Rh(III)/Pt(II) metalloinsertor conjugate

247th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.